Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
about
Azithromycin effectiveness against intracellular infections of Francisella.Azithromycin metabolite identification in plasma, bile, and tissues of the ball python (Python regius).Determination of erythromycin A in rat plasma and urine by high-performance liquid chromatography with chemiluminescence detection using Tris(2,2'-bipyridine)ruthenium(II).Detection of novel secondary metabolites.Characterization of impurities in spiramycin by liquid chromatography/ion trap mass spectrometry.Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.Intravenous azithromycin.Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin.In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.Pneumococcal macrolide resistance--myth or reality?Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.Penetration of clarithromycin into lung tissues from patients undergoing lung resectionEvaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydiaInfluence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patientsBeta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobesSingle-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditisCommonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogensPharmacokinetics of azithromycin in pediatric patients with acute otitis mediaLevels of flurithromycin in female genital tissue.Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral dosesA multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.The new macrolide antibiotics. Azithromycin and clarithromycin.Azithromycin: the first azalide antibiotic.In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics.Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.Future directions in antimicrobial chemotherapy.Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.In vivo administration of azithromycin affects lymphocyte activity in vitro.Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infectionIn vitro activity of MC-352, a new 16-membered macrolide.Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance.
P2860
Q30435916-D238BA23-D8F4-480B-B8FE-295B7E1CD012Q30909691-D9D825B2-BC3E-4487-AE4C-33E9D2BC36CCQ33235014-88EDA6DC-6AA2-4C47-83FC-1E12550AE6CCQ33289770-CD4F721F-8F59-46EE-8E98-FA159DD0874AQ33436507-56C00945-95E7-4242-B702-D5942DBA4A71Q33541485-BDF05B9D-15B6-454E-B9DD-47CAEA57C14DQ33543121-7EBFC9B4-0CFE-4EFD-9C21-7EE5DDA35C58Q33598839-7D1E758D-BDC4-4ADF-9893-2A52437DB8F6Q33693025-3F6924DF-87F7-45F2-8CD5-B6C6C2D86963Q33703410-7D11C7F1-683A-4FA0-8F5D-6361B1D90C32Q33718858-BAC75DAE-EF8E-43C9-A7E7-FDB20615B0E4Q33743899-EDA9E105-F7FF-4154-B302-C4AA5CCAD1FDQ33752955-CBF54FDB-5422-4326-A5BF-D15E2395E804Q33753604-EA0B3031-FF1B-48EE-A308-BE180FFC84EBQ33758174-AEB754BE-9B32-4BF9-BBA1-9E28F43DF8D0Q33760662-94951597-8E5F-4BFE-80EF-6F98900BD854Q33970783-8F6D6513-1114-48D3-9459-4E8FE840CEF6Q33976830-A21EF753-E33E-47AC-8B45-E47ABDCC6558Q33977802-36D8CC19-D96D-4DF5-A10C-CBACF826FBC7Q33979017-B8C5AE82-56C5-4B8B-9051-7F7177653A30Q33979902-EA8DBB80-360C-4C3D-AC5B-6362702D4ABFQ34437719-61209E61-1702-408E-8BC1-7B0E87561C63Q35111191-383AC80A-5A85-4C07-863E-1FB5A7AB6ABDQ35117726-C5704521-BA7F-4909-A9E0-0BCFF0DE729BQ35117884-2A36EBA3-50C5-4A2F-802D-31B71F3ECC5FQ35129323-7D7D13A4-AD5B-47A8-80F8-024DB8742DC1Q35138146-D40BC21B-99B7-457E-BC9E-A49CFF89D580Q35229174-5E6CECDF-800B-4E70-9BED-671EE07B114EQ35229425-ED60828C-8E5A-4C1B-884C-94B315C8DC95Q35234822-F1915A90-EC32-41F3-AC93-BB3DC3B43B70Q35275274-128DBF7F-2475-4504-9530-4914717FEC0EQ35466622-1A96DC04-1ABF-42A6-A089-BE9E1738AE74Q35530705-6E62486B-980B-4922-959A-1EB48E04E71FQ35565331-FE0AD407-CC58-4BC9-98AC-377518BC76AAQ35627730-B4480545-5F0D-4303-AB33-CE9C755C30EFQ35815229-9E2E50A4-DEB7-432D-90E7-CA7E16982E52Q35818832-7CCE7099-AB99-4FE7-81F0-CA213DFB4554Q35884831-B1F3F01A-27FC-4781-815D-A1C87CE7E84EQ35894116-AC85D400-4A48-4CF4-9224-DFE539A15972Q35897251-337A8B78-1920-403B-9361-4519AE3C4534
P2860
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@ast
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@en
type
label
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@ast
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@en
prefLabel
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@ast
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@en
P2093
P2860
P356
P1476
Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.
@en
P2093
P2860
P304
P356
10.1128/AAC.32.11.1710
P407
P577
1988-11-01T00:00:00Z